NCT04866862 is a Phase 2 clinical trial of Combination of Fruquintinib and Camrelizumab in Colorectal Neoplasm, sponsored by The First Affiliated Hospital with Nanjing Medical University.

Who is sponsoring NCT04866862?

NCT04866862 is sponsored by The First Affiliated Hospital with Nanjing Medical University.

What drugs are being tested in NCT04866862?

Interventions in NCT04866862: Combination of Fruquintinib and Camrelizumab.

What condition does NCT04866862 study?

NCT04866862 studies Colorectal Neoplasm.

Is NCT04866862 still recruiting?

NCT04866862 is currently status unknown. Last updated 25 July 2022.

Last reviewed 2022-07-25 · How we verify

NCT04866862

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer

Status unknown Phase 2 Last updated 25 July 2022

What this trial tests

Phase 2 trial testing Combination of Fruquintinib and Camrelizumab in Colorectal Neoplasm in 32 participants. Status unknown.

Timeline

26 April 2021

Primary endpoint
1 June 2024

1 June 2024

Quick facts

Lead sponsor	The First Affiliated Hospital with Nanjing Medical University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	32
Start date	26 April 2021
Primary completion	1 June 2024
Estimated completion	1 June 2024
Sites	1 location across China

Drugs / interventions tested

Combination of Fruquintinib and Camrelizumab — full drug profile →

Conditions studied

Colorectal Neoplasm — all drugs for Colorectal Neoplasm →

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Who can join

Adults 18 to 70, any sex, with Colorectal Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Limited agents are optional after standard first and second line treatment for mCRC. Nowadays, cancer therapy has entered the era of immunotherapy. The approved cancer therapies include pembrolizumab and nivolumab, but only for MSI-H patients. 95% of non MSI-H / dMMR patients with advanced colorectal cancer can not benefit from them. Therefore, the use of PD-1 / PD-L1 monoclonal antibody in mCRC is greatly limited. Our previous research showed that anti-PD-1 combined with Fruquintinib can significantly inhibit the growth of CRC in MSS mice. At the same time, a retrospective clinical study showed that patients with MSS CRC can benefit from Sintilimab combined with Fruquintinib. Camrelizumab is PD-1 monoclonal antibody, which has been approved for a variety of tumors. The prospective clinical trial of Camrelizumab combined with Fruquintinib may bring new hope for the treatment of non MSI-H / dMMR patients with mCRC.This study is aimed to explore the efficacy, safety in advanced colorectal cancer failed to standard therapy in Chinese population.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness.
Barnestein R, Galland L, Kalfeist L, Ghiringhelli F, et al · · 2022 · cited 66× · PMID 36117524 · DOI 10.1080/2162402x.2022.2120676
Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond.
Al Bitar S, El-Sabban M, Doughan S, Abou-Kheir W. · · 2023 · cited 53× · PMID 36998426 · DOI 10.3748/wjg.v29.i9.1395
Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine.
Huyghe N, Benidovskaya E, Stevens P, Van den Eynde M. · · 2022 · cited 36× · PMID 35565369 · DOI 10.3390/cancers14092241
Microsatellite Instability: From the Implementation of the Detection to a Prognostic and Predictive Role in Cancers.
Amato M, Franco R, Facchini G, Addeo R, et al · · 2022 · cited 32× · PMID 35955855 · DOI 10.3390/ijms23158726
The role of immunotherapy in microsatellites stable metastatic colorectal cancer: state of the art and future perspectives.
Gandini A, Puglisi S, Pirrone C, Martelli V, et al · · 2023 · cited 29× · PMID 37207140 · DOI 10.3389/fonc.2023.1161048
Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer.
Lavacchi D, Roviello G, Guidolin A, Romano S, et al · · 2023 · cited 10× · PMID 36982913 · DOI 10.3390/ijms24065840
The Interplay between Anti-Angiogenics and Immunotherapy in Colorectal Cancer.
Maiorano BA, Parisi A, Maiello E, Ciardiello D. · · 2022 · cited 7× · PMID 36294987 · DOI 10.3390/life12101552
The Current Role of Antiangiogenics in Colorectal Cancer.
Basile D, Di Nardo P, Daffinà MG, Cortese C, et al · · 2025 · PMID 41373757 · DOI 10.3390/ijms262311605

Verify or expand the search:

Other recruiting trials for Colorectal Neoplasm

Currently open trials in the same condition.

NCT05953662 — Safety and Efficacy of Reduced-port Laparoscopic Surgery for Patients Of Colon and Upper Rectal Cancer · NA · active not recruiting
NCT05419011 — Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome · Phase 2 · active not recruiting
NCT04185779 — COLO-COHORT (Colorectal Cancer Cohort) Study · recruiting
NCT03936530 — Infrapyloric and Greater Curvature Lymph Node Metastasis in Colon Cancer · active not recruiting
NCT02758951 — Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases · Phase 2, PHASE3 · active not recruiting

Other The First Affiliated Hospital with Nanjing Medical University trials

Trials by the same sponsor.

NCT07377981 — An Exploratory Study of the Efficacy and Safety of Esketamine and Dexmedetomidine in Non-Intubated ICU Patients With Hyp · Phase 4 · not yet recruiting
NCT07523789 — Comparison of Chemotherapy and Immunotherapy in Neoadjuvant Therapy for TNBC · not yet recruiting
NCT07464756 — SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric Cancer · Phase 2 · not yet recruiting
NCT07482826 — Full-Endoscopic Decompression vs. Endoscopic Lumbar Fusion for Middle-Aged and Older Adults With Spinal Stenosis · NA · not yet recruiting
NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04866862 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital with Nanjing Medical University
Last refreshed: 25 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04866862.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing